文献速递细菌感染、耐药与抗菌药物

泌尿生殖道淋病治疗新抗菌药物研发:临床试验设计考量

Development of New Antimicrobials for Urogenital Gonorrhea Therapy: Clinical Trial Design Considerations.
PubMed 文献 · Clin Infect Dis · 2020-01-01

本文总结近期关于泌尿生殖道淋病治疗抗菌药物评价流程的会议,指出淋病治疗推荐受抗菌药物耐药演进和新抗生素管线萎缩威胁;现有评价对药代动力学/药效学理解、耐药预防和新试验设计利用有限,并受以头孢曲松/阿奇霉素联合方案作为非劣效试验对照的要求所限;淋球菌流行病学演变和试验设计限制妨碍青少年、女性及耐药淋球菌感染者等高危人群入组。

要点

  • 现有淋病治疗推荐受耐药演进和新抗生素管线萎缩威胁。
  • 非劣效试验需以头孢曲松/阿奇霉素联合方案为对照,构成设计障碍。
  • 高危人群(青少年、女性、耐药淋球菌感染者)入组受限。

核心结论

  • 淋病仍是重大公共卫生挑战,当前治疗推荐受耐药演进和新抗生素管线萎缩威胁。
  • 现有淋病治疗评价对药代动力学/药效学、耐药预防和新试验设计利用有限,需考虑新的评价设计。

主要发现

  • 当前评价对药代动力学和药效学在有效治疗及耐药预防中的作用理解利用有限。
  • 非劣效试验要求以头孢曲松/阿奇霉素联合方案为对照,妨碍新治疗评价。
  • 淋球菌流行病学演变和试验设计限制妨碍高危人群入组。

临床怎么用

  • 本文鼓励考虑新的淋病治疗评价设计,以推进新抗菌药物研发。

局限性

  • 本文为会议总结,未报告具体试验数据或推荐条款。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gonorrhea remains a major public health challenge, and current recommendations for gonorrhea treatment are threatened by evolving antimicrobial resistance and a diminished pipeline for new antibiotics. Evaluations of potential new treatments for gonorrhea currently make limited use of new understanding of the pharmacokinetic and pharmacodynamic contributors to effective therapy, the prevention of antimicrobial resistance, and newer designs for clinical trials. They are hampered by the requirement to utilize combination ceftriaxone/azithromycin therapy as the comparator regimen in noninferiority trials designed to seek an indication for gonorrhea therapy. Evolving gonococcal epidemiology and clinical trial design constraints hinder the enrollment of those populations at the greatest risk for gonorrhea (adolescents, women, and persons infected with antibiotic-resistant Neisseria gonorrhoeae). This article summarizes a recent meeting on the evaluation process for antimicrobials for urogenital gonorrhea treatment and encourages the consideration of new designs for the evaluation of gonorrhea therapy.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hook EW, Newman L, Drusano G, et al. Development of New Antimicrobials for Urogenital Gonorrhea Therapy: Clinical Trial Design Considerations. Clin Infect Dis. 2020. PMID: 31538646. doi:10.1093/cid/ciz899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。